Alkem Laboratories has received favourable Orders-in-Appeal from the Commissioner of Income Tax, Appeal – 47, Mumbai (CIT(A)) for Assessment Years (AYs) 2018-19 to 2022-23. The orders, received on 30th June, 2026, pertain to the deletion of disallowances made under Section 80-IE of the Income-tax Act, 1961, involving a tax amount of ₹660.77 Crores. The company confirmed that there is no material impact on its financial, operational, or other activities.

Background of the Tax Dispute

The dispute originated when the Assessing Officer disallowed part of the deduction claimed under Section 80-IE of the Income-tax Act, 1961, in re-assessment orders passed under Section 143(3)/144 read with Section 147 of the Act for AYs 2018-19 to 2022-23. Alkem Laboratories subsequently filed appeals before the CIT(A), which have now been decided in the company's favour. The CIT(A) has passed orders deleting the said disallowances across all five assessment years in question.

Key Details of the Orders-in-Appeal

The following table summarises the key details of the favourable orders as disclosed by the company:

Company's Disclosure and Compliance

Alkem Laboratories confirmed that the orders have no material impact on the financial, operational, or other activities of the company. The disclosure was made in compliance with Clause 20 of Para A of Part A of Schedule III of the SEBI Listing Regulations. The information has also been made available on the company's official website at www.alkemlabs.com . The disclosure was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, on 1st July, 2026.

Alkem Laboratories Ltd has scheduled a virtual analyst and institutional investor meeting with TA Associates for July 3, 2026. The meeting is intended to discuss the company's performance and strategy, adhering to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The interaction will provide TA Associates, an institutional investor, with direct access to the company's management. This engagement is part of Alkem's routine investor relations activities to keep stakeholders informed about its operational and financial progress.

Meeting Details

The specific details of the scheduled meeting are outlined below:

The company has noted that the schedule for the aforementioned meeting is subject to change due to exigencies on the part of the investor or the company. Any modifications to the plan will be communicated through the appropriate regulatory channels.

Manish Narang, President – Legal, Company Secretary & Compliance Officer at Alkem Laboratories Ltd , signed the intimation regarding this schedule on June 29, 2026.